Chronic Heart Failure Therapeutics
1. Corlanor patent expiration
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(11 months from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(a month from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(a month from now) | |
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7879842 (Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(7 months from now) | |
|
US7361649 (Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(7 months from now) | |
|
US7361650 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(7 months from now) | |
|
US7867996 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
NCE-1 date: 16 October, 2019
Market Authorisation Date: 15 April, 2015
Dosage: TABLET
How can I launch a generic of CORLANOR before it's drug patent expiration?
More Information on Dosage
CORLANOR family patents
2. Corlanor patent expiration
Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(11 months from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(a month from now) | |
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(a month from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2020 |
| Pediatric Exclusivity(PED) | Oct 22, 2026 |
| New Product(NP) | Apr 22, 2022 |
| Orphan Drug Exclusivity(ODE-234) | Apr 22, 2026 |
Drugs and Companies using IVABRADINE ingredient
NCE-1 date: 22 October, 2025
Market Authorisation Date: 22 April, 2019
Dosage: SOLUTION
More Information on Dosage
CORLANOR family patents
3. Inpefa patent
expiration
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(2 years from now) | |
| US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(2 years from now) | |
| US8217156 | LEXICON PHARMS INC | Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use |
Oct, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Dosage: TABLET
More Information on Dosage
INPEFA family patents
4. Verquvo patent expiration
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604948 | MSD | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(6 years from now) | |
| US10736896 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| US8420656 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993476 | MSD | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| US8921377 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| US11439642 | MSD | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 19 January, 2025
Market Authorisation Date: 19 January, 2021
Dosage: TABLET
More Information on Dosage
VERQUVO family patents